Original research

Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders

Frederike Cosima Oertel 1,2,3 Hanna G Zimmermann,1,2,4 Seyedamirhosein Motamedi,1,2 Claudia Chien 1,2,5 Orhan Aktas,5 Philipp Albrecht 6,7 Marius Ringelstein 6,7,8 Anitha Dcunha,7 Lekha Pandit 7,8,9 Elena H Martinez-Lapiscina 8,9 Bernardo Sanchez-Dalmau,8 Pablo Villoslada 8,9, Jacqueline Palace,10 Adriana Roca-Fernández 10,14 Maria Isabel Leite,10 Srilakshmi M Sharma,11 Letizia Leocani,12 Marco Pisa,12 Marta Radaelli,12 Marco Aurélio Lana-Peixoto,13 Mariana Andrade Fontenelle,13 Joachim Havla 14,15 Fereshteh Ashtari,15 Rahele Kafieh,16 Alireza Dehghani,17 Mohsen Pourazizi,17 Romain Marignier,18 Alvaro Cobo-Calvo,18,19 Nasrin Asgari,20,21 Anu Jacob,22,23 Saif Huda,22,23 Yang Mao-Draayer,24 Ari J Green,3 Rachel Kenney,25 Michael R Yeaman,26,27 Terry J Smith,28,29 Lawrence Cook,30 Alexander U Brandt,1,2,31 Friedemann Paul,1,2,32 Axel Petzold 33,34

ABSTRACT

Background The novel optic neuritis (ON) diagnostic criteria include intereye differences (IED) of optical coherence tomography (OCT) parameters. IED has proven valuable for ON diagnosis in multiple sclerosis but has not been evaluated in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders (AQP4+NMOSD). We evaluated the diagnostic accuracy of intereye absolute (IEAD) and percentage difference (IEPD) in AQP4+NMOSD after unilateral ON >6 months before OCT as compared with healthy controls (HC).

Methods Twenty-eight AQP4+NMOSD after unilateral ON (NMOSD-ON), 62 HC and 45 AQP4+NMOSD without ON history (NMOSD-NON) were recruited by 13 centres as part of the international Collaborative Retrospective Study on retinal OCT in Neuromyelitis Optica study. Mean thickness of peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell layer and inner plexiform layer (GCIP) were quantified by Spectralis spectral domain OCT. Threshold values of the ON diagnostic criteria (pRNFL: IEAD 5 µm, IEPD 5%; GCIP: IEAD 4 µm, IEPD 4%) were evaluated using receiver operating characteristics and area under the curve (AUC) metrics.

Results The discriminative power was high for NMOSD-ON versus HC for IEAD (pRNFL: AUC 0.95, specificity 82%, sensitivity 86%; GCIP: AUC 0.93, specificity 98%, sensitivity 75%) and IEPD (pRNFL: AUC 0.96, specificity 87%, sensitivity 89%; GCIP: AUC 0.94, specificity 96%, sensitivity 82%). The discriminative power was high/moderate for NMOSD-ON versus NMOSD-NON for IEAD (pRNFL: AUC 0.92, specificity 77%, sensitivity 86%; GCIP: AUC 0.87, specificity 85%, sensitivity 75%) and for IEPD (pRNFL: AUC 0.94, specificity 82%, sensitivity 89%; GCIP: AUC 0.88, specificity 82%, sensitivity 82%).

Conclusions Results support the validation of the IED metrics as OCT parameters of the novel diagnostic ON criteria in AQP4+NMOSD.

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ The novel optic neuritis (ON) diagnostic criteria include intereye differences (IED) of neuroaxonal optical coherence tomography (OCT) parameters.
⇒ IED has proven valuable for ON diagnosis in multiple sclerosis but has not been evaluated in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders (AQP4+NMOSD).

WHAT THIS STUDY ADDS
⇒ In this cohort study that included 73 AQP4+NMOSD patients and 62 healthy controls from 13 centres, the discriminative power of intereye differences of neuroaxonal OCT parameters was high for AQP4+NMOSD with a history of one unilateral ON event versus healthy controls (specificity ≥82%, sensitivity ≥75%) as well as versus AQP4+NMOSD without a history of ON (specificity ≥77%, sensitivity ≥75%).

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
⇒ OCT parameters of novel diagnostic ON criteria are applicable in AQP4+NMOSD.
BACKGROUND

Long-awaited diagnostic criteria and a new classification schema for optic neuritis (ON) have recently been defined by an expert consortium. As part of these criteria, the increasing value of optical coherence tomography (OCT) as an accurate method for quantitative assessment of retinal neurodegeneration after ON in clinical diagnosis and monitoring has been recognised.

In addition to monocular atrophy of the peripapillary retinal nerve fibre layer (pRNFL) and of the combined ganglion cell and inner plexiform layer (GCIPL), retinal asymmetry of pRNFL and of the combined ganglion cell and inner plexiform layer (GCIPL) can be used as a diagnostic tool for retinal neurodegeneration after ON. In multiple sclerosis (MS), an intereye absolute difference (IEAD) of >3–5 µm and intereye percentage difference (IEPD) of >3%–5% are diagnostic for a history of unilateral ON and can reach a specificity up to 97% and sensitivity of up to 100%. Yet, outside of MS cohorts, ON associations with intereye differences have not been validated in other disorders.

Patients with aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) frequently suffer from severe and recurrent ON episodes. Due to the relative rarity of these patients as compared with MS, diagnosis and appropriate treatment are often delayed. Furthermore, ON in AQP4-IgG seropositive NMOSD can present with an atypical clinical picture more commonly than in MS. In turn, inaccurate and/or delayed diagnoses can significantly negatively affect long-term clinical outcomes. Thus, IEAD and IEPD could be valuable additions to the diagnostic workup of ON in AQP4-IgG seropositive NMOSD. Yet, it remains unclear if the threshold values defined by the novel ON diagnostic criteria and established in MS are also applicable in AQP4-IgG seropositive NMOSD. Therefore, this study aims to evaluate the diagnostic accuracy of reported IEAD and IEPD values for AQP4-IgG seropositive NMOSD patients with one unilateral ON event (NMOSD-ON) as compared with healthy controls (HC).

METHODS

Cohort design

We included AQP4-IgG seropositive NMOSD patients with a history of one unilateral ON (NMOSD-ON) >6 months before OCT measurements and two groups for comparison: (1) HC and (2) AQP4-IgG seropositive NMOSD patients without a history of ON (NMOSD-NON). All NMOSD and HC subjects were recruited as part of the international Collaborative Retrospective Study on retinal OCT in Neuromyelitis Optica (CROCTINO) study and their data were acquired by 13 international centres between 2000 and 2018 (online supplemental table 1). Inclusion criteria were: (1) OCT data acquired by Spectralis SD-OCT devices, (2) the absence of diseases potentially confounding OCT analyses (such as glaucoma, retinal surgery and ametropia >6 D) and (3) the absence of (further) ON attacks within 6 months before the examination date. Clinical data including time since disease onset, time since ON and treatment history were collected at the discretion of each centre. AQP4-IgG antibodies

Table 1 Demographic overview

<table>
<thead>
<tr>
<th></th>
<th>HC</th>
<th>NMOSD-NON</th>
<th>NMOSD-ON</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects (n)</td>
<td>62</td>
<td>45</td>
<td>28</td>
</tr>
<tr>
<td>Eyes (n)</td>
<td>124</td>
<td>90</td>
<td>56</td>
</tr>
<tr>
<td>Patients with a disease duration &lt;10 years (n)</td>
<td>.</td>
<td>43</td>
<td>21</td>
</tr>
<tr>
<td>Patients with ON as first manifestation (n)</td>
<td>.</td>
<td>.</td>
<td>17</td>
</tr>
<tr>
<td>Age (year, mean±SD)</td>
<td>37.7±10.2</td>
<td>39.0±10.4</td>
<td>38.8±12.1</td>
</tr>
<tr>
<td>Sex (male, n (%))</td>
<td>20 (32)</td>
<td>2 (4)</td>
<td>3 (11)</td>
</tr>
<tr>
<td>Time since ON (year, median (min–max))</td>
<td>.</td>
<td>.</td>
<td>2.8 (0.7–19.5)</td>
</tr>
<tr>
<td>Time since onset (year, mean±SD)</td>
<td>3.8±4.0</td>
<td>6.5±5.6</td>
<td></td>
</tr>
<tr>
<td>pRNFL thickness (µm, mean±SD)</td>
<td>98.5±9.4</td>
<td>98.8±10.8</td>
<td>80.7±24.9</td>
</tr>
<tr>
<td>pRNFL IEPD (%)</td>
<td>2.7±2.3</td>
<td>3.7±4.4</td>
<td>28.6±19.9</td>
</tr>
<tr>
<td>pRNFL IEAD (µm, mean±SD)</td>
<td>2.7±2.2</td>
<td>3.8±4.5</td>
<td>27.0±19.8</td>
</tr>
<tr>
<td>GCIPL thickness (µm, mean±SD)</td>
<td>79.9±5.3</td>
<td>77.6±6.3</td>
<td>66.3±13.2</td>
</tr>
<tr>
<td>GCIPL IEPD (%)</td>
<td>1.3±1.1</td>
<td>2.7±3.5</td>
<td>19.0±14.3</td>
</tr>
<tr>
<td>GCIPL IEAD (µm, mean±SD)</td>
<td>1.0±0.9</td>
<td>2.1±2.9</td>
<td>14.1±10.9</td>
</tr>
</tbody>
</table>

GCIPL, combined ganglion cell and inner plexiform layer; HC, healthy control; IEAD, intereye absolute difference; IEPD, intereye percentage difference; NMOSD-NON, patients with aquaporin-4-antibody seropositive neuromyelitis optica spectrum disorders and no history of optic neuritis; NMOSD-ON, patients with aquaporin-4-antibody seropositive neuromyelitis optica spectrum disorders and a history of unilateral optic neuritis; ON, optic neuritis; pRNFL, peripapillary retinal nerve fibre layer.

Table 2 Comparison of IEAD and IEPD value for GCIPL and pRNFL

<table>
<thead>
<tr>
<th></th>
<th>NMOSD-ON versus HC</th>
<th>NMOSD-ON versus NMOSD-NON</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T value  P value</td>
<td>T value  P value</td>
</tr>
<tr>
<td>All subjects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pRNFL IEPD (%)</td>
<td>−6.885 &lt;0.001</td>
<td>−6.519 &lt;0.001</td>
</tr>
<tr>
<td>pRNFL IEAD (µm)</td>
<td>−6.483 &lt;0.001</td>
<td>−5.102 &lt;0.001</td>
</tr>
<tr>
<td>GCIPL IEPD (%)</td>
<td>−6.566 &lt;0.001</td>
<td>−6.928 &lt;0.001</td>
</tr>
<tr>
<td>GCIPL IEAD (µm)</td>
<td>−6.338 &lt;0.001</td>
<td>−5.663 &lt;0.001</td>
</tr>
<tr>
<td>First attack only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pRNFL IEPD (%)</td>
<td>−6.162 &lt;0.001</td>
<td>−5.892 &lt;0.001</td>
</tr>
<tr>
<td>pRNFL IEAD (µm)</td>
<td>−5.969 &lt;0.001</td>
<td>−5.677 &lt;0.001</td>
</tr>
<tr>
<td>GCIPL IEPD (%)</td>
<td>−6.570 &lt;0.001</td>
<td>−6.024 &lt;0.001</td>
</tr>
<tr>
<td>GCIPL IEAD (µm)</td>
<td>−6.357 &lt;0.001</td>
<td>−5.778 &lt;0.001</td>
</tr>
<tr>
<td>Recent onset (&lt;10 years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pRNFL IEPD (%)</td>
<td>−6.527 &lt;0.001</td>
<td>−6.201 &lt;0.001</td>
</tr>
<tr>
<td>pRNFL IEAD (µm)</td>
<td>−6.054 &lt;0.001</td>
<td>−5.708 &lt;0.001</td>
</tr>
<tr>
<td>GCIPL IEPD (%)</td>
<td>−5.768 &lt;0.001</td>
<td>−5.274 &lt;0.001</td>
</tr>
<tr>
<td>GCIPL IEAD (µm)</td>
<td>−5.530 &lt;0.001</td>
<td>−5.014 &lt;0.001</td>
</tr>
</tbody>
</table>

GCIPL, combined ganglion cell and inner plexiform layer; HC, healthy control; IEAD, intereye absolute difference; IEPD, intereye percentage difference; NMOSD-NON, patients with aquaporin-4-antibody seropositive neuromyelitis optica spectrum disorders and no history of optic neuritis; NMOSD-ON, patients with aquaporin-4-antibody seropositive neuromyelitis optica spectrum disorders and a history of unilateral optic neuritis; ON, optic neuritis; pRNFL, peripapillary retinal nerve fibre layer.
were detected in serum samples of all NMOSD patients by cell-based assays.17

Data are reported according to the Enhancing the Quality and Transparency Of Health Research reporting guidelines.18

Optical coherence tomography
All OCT examinations were conducted at each centre using Spectralis SD-OCT devices (Heidelberg Engineering, Heidelberg, Germany). pRNFL thickness was measured using a 12° or 3.5 mm diameter peripapillary ring scan. Macular GCIPL thickness was calculated using a 5 mm diameter annulus around the fovea excluding the central 1 mm diameter cylinder from a volume scan. All OCT data reading was performed at Charité Universitätsmedizin Berlin by five graders as previously described.14 All included OCT images fulfilled OSCAR-IB criteria19 20 and are presented adhering to the Apostel V.2.0 recommendations.21 22

Statistical analyses
Statistical analyses were conducted using R (V.4.2.1) (RStudio, Boston, Massachusetts, USA).23 Data were stratified in cohorts by diagnosis and history of ON. Continuous data were described as mean±SD, if not stated otherwise. IEAD was calculated as absolute difference between eyes in pRNFL or GCIPL, respectively. IEPD was calculated as IEAD divided by the higher pRNFL or GCIPL value, respectively (comparing both eyes of the patient). Age, IEAD and IEPD were compared between groups employing unpaired t-test. Significance was established at p<0.05. The level of diagnostic accuracy was evaluated using receiver operating characteristics (ROC) curves. Area under the curve (AUC) measurements were rated as low/no discriminative power (for AUC <0.7), moderate discriminative power (for AUC 0.7–0.9) and high discriminative power (for AUC >0.9).

Data availability
All data used in this project are available within the article and by reasonable request from the corresponding author.

RESULTS
Cohort
Characteristics of the study cohort are summarised in table 1. Twenty-eight patients (56 eyes) with a diagnosis of AQP4-IgG seropositive NMOSD and a history of unilateral ON (NMOSD-ON) were compared with 62 healthy controls (HC, 124 eyes) and 45 patients with AQP4-IgG seropositive NMOSD without a history of ON (NMOSD-NON, 90 eyes). All control groups were age-matched with NMOSD-ON (HC: p=0.881, NMOSD-NON: p=0.942).

Twenty-one NMOSD-ON (42 eyes, age: 36.2±11.5, sex (male, n (%)): 2 (10)) and 43 NMOSD-NON (86 eyes, age: 38.4±10.3, sex (male, n (%)): 2 (5)) had a disease duration <10 years. For 17 NMOSD-ON (34 eyes, age: 39.2±12.2, sex (male, n (%)): 2 (12)), the unilateral ON episode was their first disease manifestation.

Intereye percentage and absolute differences
The IEAD and IEPD of pRNFL and GCIPL was higher in NMOSD-ON compared with HC and NMOSD-NON (table 2)
and figures 1 and 2). This result was highly significant for both parameters (p<0.001) when comparing the whole cohort as well as subsets with (a) the unilateral ON episode as the first attack and (b) disease duration <10 years.

**Diagnostic sensitivity and specificity of intereye differences in NMOSD**

The discriminative power for IEPD and IEAD was high (AUC >0.9) for HC versus NMOSD-ON. This outcome was true for patients overall, and for patients with a disease duration <10 years (figures 3 and 4). The discriminative power for IEPD and IEAD was also high or moderate (AUC 0.8–0.9) for separating NMOSD-NON versus NMOSD-ON.

Evaluating previously reported threshold values (IEAD: 5 µm, IEPD: 5% for pRNFL and IEAD: 4 µm, IEPD: 4% GCIPL), NMOSD-ON could be separated with high discriminative power from HC using IEAD for pRNFL with a specificity of 82% and a sensitivity of 86% (AUC 0.95, positive predictive value (PPV) 0.68, negative predictive value (NPV) 0.93). Likewise, discriminative power was high using IEPD for pRNFL with a specificity of 87% and a sensitivity of 89% (AUC 0.96, PPV 0.76, NPV 0.95). NMOSD-ON could be equally well distinguished from HC using IEAD for GCIPL with a specificity of 98% and a sensitivity of 75% (AUC 0.87, PPV 0.76, NPV 0.85) and using IEPD for GCIPL with a specificity of 85% and a sensitivity of 75% (AUC 0.87, PPV 0.76, NPV 0.85). ROC results of IEAD and IEPD did not differ significantly for any discrimination (data not shown).

**DISCUSSION**

The identification of prior ON episodes is a valuable step in the diagnostic workup and differential diagnosis of multiple autoimmune neuroinflammatory diseases such as AQP4-IgG seropositive NMOSD and MS. Whereas IEPD and IEAD previously proved their diagnostic value in the ON workup of patients with MS, our study demonstrates for the first time a high diagnostic accuracy of intereye difference metrics for the identification of AQP4-IgG seropositive NMOSD patients with a prior unilateral ON episode (>6 months before OCT), as compared with NMOSD patients without prior ON episodes and HC. The data also provide support for the macular GCIPL IEAD (4 µm), and IEPD (4%) thresholds as defined in the novel ON diagnostic criteria as having excellent diagnostic sensitivity and specificity for ON in AQP4-IgG seropositive NMOSD. Intereye difference metrics thereby prove to not be specific or limited to a particular demyelinating disease, but rather a reflection of the thinning of the RNFL and GCIPL that occurs after ON associated with many autoimmune neuroinflammatory diseases. The fact that
Neuro-inflammation

these findings were consistent across an array of international centres is also encouraging with respect to uniform application of these methods and outcome interpretations with minimised centre bias globally.

The IEPD and IEAD performed equally well in our study suggesting that intereye difference metrics may not require the establishment of separate reference values for different OCT devices. Rather, it is conceivable that the IEPD threshold could be used across heterogenous devices and cohorts. Interestingly, both pRNFL and GCIPL results provided comparable assessments in this cohort, extending the application of intereye differences. Whereas pRNFL may be the faster in a standard clinical setting, GCIPL undergoes less edematous change and may therefore have special utility earlier after acute ON episodes or in clinical ON trials. The effects of recurrent or bilateral ON attacks and of chiasmic involvement on the IEAD and IEPD, as commonly seen in NMOSD-ON, are not known. Therefore, future studies should interrogate the validity of these measurements longitudinally in NMOSD-ON.

A strength of our study rests on its size and multicentre setting since the cohort was derived from a consortium of expert NMOSD researchers in context of the international CROCTINO cohort. Hence, the significance of the results suggests that potential differences in use of OCT across broad geographic

**Figure 3** ROC curves for IEPD for (A-B, E-F) pRNFL and (C-D, G-H) GCIPL discriminating between (A, C, E, G) NMO-ON versus HC, and (B, D, F, H) NMO-ON versus NMOSD-NON. ROC curves are plotted for (A-D) all subjects and (E-H) NMO-ON and NMOSD-NON patients with a disease duration <10 years and HC. AUC, area under the curve; GCIPL, combined ganglion cell and inner plexiform layer; HC, healthy controls; IEPD, intereye percentage difference, NMO-ON, patients with aquaporin-4-antibody seropositive neuromyelitis optica spectrum disorders and a history of unilateral optic neuritis; NMOSD-NON, patients with aquaporin-4-antibody seropositive neuromyelitis optica spectrum disorders and no history of optic neuritis; pRNFL, peripapillary retina nerve fibre layer; ROC, receiver operating characteristics.

**Figure 4** ROC curves for IEAD for (A-B, E-F) pRNFL and (C-D, G-H) GCIPL (A, D) discriminating between (A, C, E, G) NMO-ON versus HC and (B, D, F, H) NMO-ON versus NMOSD-NON. ROC curves are plotted for (A-D) all subjects and (E-H) NMO-ON and NMOSD-NON patients with a disease duration <10 years and HC. AUC, area under the curve; GCIPL, combined ganglion cell and inner plexiform layer; HC, healthy controls; IEAD, intereye absolute difference, NMO-ON, patients with aquaporin-4-antibody seropositive neuromyelitis optica spectrum disorders and a history of unilateral optic neuritis; NMOSD-NON, patients with aquaporin-4-antibody seropositive neuromyelitis optica spectrum disorders and no history of optic neuritis; pRNFL, peripapillary retina nerve fibre layer; ROC, receiver operating characteristics.
distances and ethnicities are overcome by the methods of acquisition and analysis used here. Yet, limitations of the current study should also be considered. First, the cohorts were not matched for gender or degree of loss of neurological function, preventing statistical evaluation. Furthermore, the prevalence of unilateral ON in our cohort is higher than expected in a real-world setting, thereby influencing PPV and NPV calculations. Also, no functional metrics such as visually evoked potentials, or MRI were included in this study, thus subclinical contralateral optic nerve involvement, which would affect IED measurements, cannot be excluded. Therefore, it remains uncertain if there is added diagnostic value of MRI and visually evoked potentials. This determination will be important for future, especially prospective, studies to further improve on diagnostic sensitivity. Nonetheless, the current findings show the astonishing value of quantitative intereye differences for ON diagnosis in AQP4-IgG seropositive NMOSD. This might be of value in making a clinical diagnosis and defining inclusion criteria for clinical trials in NMOSD.

Author affiliations
1NeuroCure Clinical Research Center, Charité – Universitätmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
3Department of Neurology, University of California San Francisco, San Francisco, California, USA
4Einstein Center Digital Future, Berlin, Germany
5Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
6Centre for Neurology and Neuropsychiatry, Landschaftsverband Rheinland-Klinikum Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
7Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India
8Hospital Clinic de Barcelona-Institut d’Investigacions, Biomèdiques August Pi Sunyer, (IDIBAPS), Barcelona, Spain
9Wu Tsai Neurosciences Institute, Stanford University, Palo Alto, California, USA
10Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
11Department of Ophthalmology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
12Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE), Scientific Institute San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
13CIEM MS Research Center, University of Minas Gerais, Medical School, Belo Horizonte, Brazil
14Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians Universität München, Munich, Germany
15Kashani MS Center, Isfahan University of Medical Sciences, Isfahan, Iran
16School of advanced technologies in medicine and Medical Image and Signal processing Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
17Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
18Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France
19Centre d’Esclerosis Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
20Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
21Departments of Neurology, St. Peter’s Hospital, St. Peter’s, London, United Kingdom
22Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
23Department of Neurology, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
24Department of Neurology, University of Michigan Medical School, Ann Arbor, Michigan, USA
25Department of Medicine, Division of Molecular Medicine & Infectious Diseases, Harbor-University of California at Los Angeles (UCLA) Medical Center, and Lundquist Institute for Biomedical Innovation, Torrance, California, USA
26Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
27Departments of Neurology, Slagelse Hospitals Denmark, Institute of Regional Neurology, Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France
28Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
29Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India
30Department of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
31Department of Ophthalmology, Oxford University Hospitals, National Health Service Trust, Oxford, UK
32Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA
33Department of Neurology, University of California, Irvine, Irvine, California, USA
34Department of Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
35Moorfield’s Eye Hospital, The National Hospital for Neurology and Neurosurgery, Queen Square Institute of Neurology, University College London, London, UK
36Neuro-ophthalmology Expert Center, Amsterdam UMC, Amsterdam, Netherlands
been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**
Frederike Cosima Oertel http://orcid.org/0000-0003-4906-5983
Claudia Chien http://orcid.org/0000-0001-8280-9513
Philipp Albrecht http://orcid.org/0000-0001-7987-658X
Marius Ringelstein http://orcid.org/0000-0003-3618-8407


**REFERENCES**
